Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 18/20 | 1.00 |
| ▸ | KIT | P10721 | 17/20 | 1.00 |
| ▸ | SRC | P12931 | 3/20 | 0.57 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.57 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20580475 | 0.99 | FLT3 (1.00) | FLT3KITSRCNTRK1CHEK1 | |
| SCHEMBL21028279 | 0.91 | KIT (0.84) | FLT3KITSRCNTRK1CHEK1 | |
| Hydrochloric Acid SCHEMBL20580463 | 0.91 | KIT (0.84) | FLT3KITSRCNTRK1CHEK1 | |
| SCHEMBL4587539 | 0.81 | KIT (0.68) | FLT3KITSRCKDR | |
| SCHEMBL4586176 | 0.76 | KIT (0.62) | FLT3KITSRCAURKAKDR | |
| SCHEMBL29616336 | 0.75 | FLT3 (0.60) | FLT3KITSRCNTRK1AURKA | |
| SCHEMBL21028276 | 0.75 | KIT (1.00) | FLT3KITSRCNTRK1 | |
| SCHEMBL21028275 | 0.75 | KIT (1.00) | FLT3KITSRCNTRK1 | |
| SCHEMBL13982226 | 0.74 | LCK (0.77) | FLT3KITSRCAURKAKDR | |
| Hydrochloric Acid SCHEMBL20580885 | 0.74 | KIT (1.00) | FLT3KITSRCNTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10300061-B2 | Aminothiazole compounds as protein kinase inhibitors | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2019-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10300061-B2 | Aminothiazole compounds as protein kinase inhibitors | ABL1, ERBB2, CSNK1E | FLT3 207/4885KIT 611/4885SRC 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.